Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer

BACKGROUND: Systemic androgen deprivation therapy (ADT), also referred to as hormone therapy, has long been the primary treatment for metastatic prostate cancer. Additional agents have been reserved for the castrate‐resistant disease stage when ADT start becoming less effective. Abiraterone is an ag...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cochrane Database Syst Rev
Asıl Yazarlar: Sathianathen, Niranjan J, Oestreich, Makinna C, Brown, Sarah Jane, Gupta, Shilpa, Konety, Badrinath R, Dahm, Philipp, Kunath, Frank
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Ltd 2020
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8092456/
https://ncbi.nlm.nih.gov/pubmed/33314020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013245.pub2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller